Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588463 | 1.00 | TAAR1 (0.42) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL13818150 | 0.91 | TAAR1 (0.47) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL4824953 | 0.84 | GRM4 (0.44) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL4598374 | 0.84 | GRM4 (0.44) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL14159195 | 0.84 | TAAR1 (0.58) | TAAR1HSD17B10ALDH1A1CASP1MC4R | |
| SCHEMBL26506434 | 0.83 | GRM4 (0.43) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL25139931 | 0.81 | TAAR1 (0.39) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL18735699 | 0.81 | TAAR1 (0.39) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL21883928 | 0.81 | TAAR1 (0.40) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL21883953 | 0.81 | TAAR1 (0.39) | TAAR1GRM4CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-2237799-B1 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2019-04-10 | — | — | EP | disclosed |
| EP-3050576-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | Ascendis Pharma Growth Disorders Division A/S (DK) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | TAAR1 2537/4885GRM4 1592/4885CTSB 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.